**Core Concept**
Tranexamic acid (TXA) is an antifibrinolytic agent that works by inhibiting the breakdown of fibrin clots, thereby preventing excessive bleeding. Its mechanism of action is centered around the inhibition of plasminogen activators and plasmin, the key enzymes responsible for fibrinolysis.

**Why the Correct Answer is Right**
Tranexamic acid exerts its effect by competitively inhibiting the binding of plasminogen to its receptors on the surface of endothelial cells. This prevents the activation of plasminogen to plasmin, the enzyme that breaks down fibrin clots. As a result, TXA increases the stability of fibrin clots and reduces the risk of bleeding. Additionally, TXA also inhibits the action of plasmin, which further contributes to its antifibrinolytic effect.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not accurately describe the mechanism of action of tranexamic acid. While TXA does have some effect on platelet aggregation, this is not its primary mechanism of action.
**Option B:** This option is incorrect because it suggests that tranexamic acid works by stimulating the production of fibrinogen. In reality, TXA works by inhibiting the breakdown of fibrin clots, not by increasing their formation.
**Option C:** This option is incorrect because it implies that tranexamic acid works by inhibiting the action of thrombin. While thrombin is an enzyme involved in the coagulation cascade, TXA's primary mechanism of action is related to the inhibition of plasminogen activators and plasmin.

**Clinical Pearl / High-Yield Fact**
TXA has been shown to reduce mortality and morbidity in patients with severe bleeding, particularly in the context of trauma and surgery. It is often used as an adjunct to standard hemostatic measures in these situations.

**Correct Answer:** C. Inhibits plasminogen activators and plasmin, thereby preventing excessive bleeding.